Paul Finn, CSO, will be attending ASM Microbe 2022, 9-13 June in Washington D.C. USA and making an Oral Presentation on Saturday 11 June at 14:15 EDT entitled “Discovery of potent Gram-negative antibacterials targeting leucyl-tRNA synthetase”. The presentation will describe the work at Oxford Drug Design that has led to the identification of multiple new inhibitor chemotypes with Gram-negative spectrum of action using its in-house computational chemistry and machine learning expertise.